Home Featured Page 14

Featured

Latest

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special...

Natural Medicine Advisory Bulletin 15: A Duplicitous December

Pot for the People: Debunking Cannabis Myths and Empowering Consumers

How Psychedelics Can Help Build a Better You: The Power in...

Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24,...

Taking the Leap: Skydiving, Psychedelics, and Unlocking Personal Potential

Psychedelic Alpha’s Top 11 Stories from 2024

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

1...131415...292 Page 14 of 292

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special...

Natural Medicine Advisory Bulletin 15: A Duplicitous December

Pot for the People: Debunking Cannabis Myths and Empowering Consumers

How Psychedelics Can Help Build a Better You: The Power in...

Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24,...

Taking the Leap: Skydiving, Psychedelics, and Unlocking Personal Potential

Psychedelic Alpha’s Top 11 Stories from 2024

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY